Posts Tagged ‘CMS’
BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy
BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy On April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm — along with other drugs like it — to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and…
Read MoreCMS decision not to cover Alzheimer’s treatment a bad one
CMS decision not to cover Alzheimer’s treatment a bad one NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease. Restricting coverage is a bad idea…
Read More